Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Sep;22(3):499–507. doi: 10.1128/aac.22.3.499

Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice.

R F Schinazi, J Peters, C C Williams, D Chance, A J Nahmias
PMCID: PMC183772  PMID: 6182836

Abstract

The combination of various concentrations of acyclovir and vidarabine or its 5'-monophosphate usually produced an additive interaction with various strains of herpes simplex virus types 1 and 2 in Vero cells. Similarly, certain combinations of these drugs were more effective than the individual drugs in decreasing the mortality and increasing the mean day of death of mice inoculated intracerebrally with herpes simplex virus type 2. Neither antagonism nor interference was noted for any of the in vitro or in vivo combinations. The increased antiviral activity was determined not to be secondary to toxic effects of the drugs. Although viruses resistant to either vidarabine or acyclovir developed readily in cell culture, no evidence of cross-resistance was obtained. Furthermore, in the presence of the two drugs, mutants resistant to vidarabine, acyclovir, or vidarabine/acyclovir could not be isolated. These findings suggest that combinations with these antivirals, which are currently being evaluated singly for the therapy of severe forms of herpetic infection, could prove clinically useful if increasing numbers of resistant viral strains are observed.

Full text

PDF
505

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryson Y. J., Kronenberg L. H. Combined antiviral effects of interferon, adenine, arabinoside, hypoxanthine arabinoside, and adenine arabinoside-5'-monophosphate in human fibroblast cultures. Antimicrob Agents Chemother. 1977 Feb;11(2):299–306. doi: 10.1128/aac.11.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burns W. H., Saral R., Santos G. W., Laskin O. L., Lietman P. S., McLaren C., Barry D. W. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet. 1982 Feb 20;1(8269):421–423. doi: 10.1016/s0140-6736(82)91620-8. [DOI] [PubMed] [Google Scholar]
  3. Champney K. J., Lauter C. B., Bailey E. J., Lerner A. M. Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination. J Clin Invest. 1978 Dec;62(6):1142–1153. doi: 10.1172/JCI109233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chapman J. R., Bridgen D. Transient renal impairment during intravenous acyclovir therapy. Lancet. 1981 Nov 14;2(8255):1103–1103. doi: 10.1016/s0140-6736(81)91292-7. [DOI] [PubMed] [Google Scholar]
  5. Coen D. M., Furman P. A., Gelep P. T., Schaffer P. A. Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-beta-D-arabinofuranosyladenine. J Virol. 1982 Mar;41(3):909–918. doi: 10.1128/jvi.41.3.909-918.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Collins P., Bauer D. J. Relative potencies of anti-herpes compounds. Ann N Y Acad Sci. 1977 Mar 4;284:49–59. doi: 10.1111/j.1749-6632.1977.tb21936.x. [DOI] [PubMed] [Google Scholar]
  7. Coster D. J., Jones B. R., McGill J. I. Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine. Br J Ophthalmol. 1979 Jun;63(6):418–421. doi: 10.1136/bjo.63.6.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crumpacker C. S., Schnipper L. E., Marlowe S. I., Kowalsky P. N., Hershey B. J., Levin M. J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982 Feb 11;306(6):343–346. doi: 10.1056/NEJM198202113060606. [DOI] [PubMed] [Google Scholar]
  9. Crumpacker C. S., Schnipper L. E., Zaia J. A., Levin M. J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother. 1979 May;15(5):642–645. doi: 10.1128/aac.15.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Desmyter J., Melnick J. L., Rawls W. E. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol. 1968 Oct;2(10):955–961. doi: 10.1128/jvi.2.10.955-961.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dowdle W. R., Nahmias A. J., Harwell R. W., Pauls F. P. Association of antigenic type of Herpesvirus hominis with site of viral recovery. J Immunol. 1967 Nov;99(5):974–980. [PubMed] [Google Scholar]
  12. Ejercito P. M., Kieff E. D., Roizman B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol. 1968 May;2(3):357–364. doi: 10.1099/0022-1317-2-3-357. [DOI] [PubMed] [Google Scholar]
  13. Field H. J., Darby G., Wildy P. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol. 1980 Jul;49(1):115–124. doi: 10.1099/0022-1317-49-1-115. [DOI] [PubMed] [Google Scholar]
  14. Field H., McMillan A., Darby G. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. J Infect Dis. 1981 Feb;143(2):281–285. doi: 10.1093/infdis/143.2.281. [DOI] [PubMed] [Google Scholar]
  15. Hirano A., Yumura K., Kurimura T., Katsumoto T., Moriyama H., Manabe R. Analysis of herpes simplex virus isolated from patients with recurrent herpes keratitis exhibiting "treatment-resistance" to 5-iodo-2'-deoxyuridine. Acta Virol. 1979 May;23(3):226–230. [PubMed] [Google Scholar]
  16. Hyndiuk R. A., Charlin R. E., Alpren T. V., Schultz R. O. Trifluridine in resistant human herpetic keratitis. Arch Ophthalmol. 1978 Oct;96(10):1839–1841. doi: 10.1001/archopht.1978.03910060351011. [DOI] [PubMed] [Google Scholar]
  17. Nordenfelt L., Nordenfelt E. Ocular herpes simplex infection. A clinical evaluation of virus isolation and studies on iodo-deoxyuridine resistance. Acta Ophthalmol (Copenh) 1977 Dec;55(6):919–926. doi: 10.1111/j.1755-3768.1977.tb05672.x. [DOI] [PubMed] [Google Scholar]
  18. North T. W., Cohen S. S. Aranucleosides and aranucleotides in viral chemotherapy. Pharmacol Ther. 1979;4(1):81–108. doi: 10.1016/0163-7258(79)90016-0. [DOI] [PubMed] [Google Scholar]
  19. O'Meara A., Hillary I. B. Acyclovir in the management of herpes virus infections in immunosuppressed children. Ir J Med Sci. 1981 Mar;150(3):73–77. doi: 10.1007/BF02938203. [DOI] [PubMed] [Google Scholar]
  20. Park N. H., Pavan-Langston D., McLean S. L., Albert D. M. Therapy of experimental herpes simplex encephalitis with aciclovir in mice. Antimicrob Agents Chemother. 1979 Jun;15(6):775–779. doi: 10.1128/aac.15.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sacks S. L., Smith J. L., Pollard R. B., Sawhney V., Mahol A. S., Gregory P., Merigan T. C., Robinson W. S. Toxicity of vidarabine. JAMA. 1979 Jan 5;241(1):28–29. doi: 10.1001/jama.1979.03290270020010. [DOI] [PubMed] [Google Scholar]
  22. Saral R., Burns W. H., Laskin O. L., Santos G. W., Lietman P. S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981 Jul 9;305(2):63–67. doi: 10.1056/NEJM198107093050202. [DOI] [PubMed] [Google Scholar]
  23. Smith K. O., Kennell W. L., Poirier R. H., Lynd F. T. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine). Antimicrob Agents Chemother. 1980 Feb;17(2):144–150. doi: 10.1128/aac.17.2.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Stanwick T. L., Schinazi R. F., Campbell D. E., Nahmias A. J. Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1981 Apr;19(4):672–674. doi: 10.1128/aac.19.4.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Travers J. P., Patterson A. A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis. J Int Med Res. 1978;6(2):102–104. doi: 10.1177/030006057800600205. [DOI] [PubMed] [Google Scholar]
  26. Valeriote F., Lin H. s. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep. 1975 Sep-Oct;59(5):895–900. [PubMed] [Google Scholar]
  27. Whitley R., Alford C., Hess F., Buchanan R. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 1980 Oct;20(4):267–282. doi: 10.2165/00003495-198020040-00002. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES